GAB1 – novel regulator of migration capacity and tonic AKT activity in CLL: Implications for combinatorial therapy with BCR inhibitors.
Authors | |
---|---|
Year of publication | 2021 |
Type | Conference abstract |
MU Faculty or unit | |
Citation | |
Related projects: |
Authors | |
---|---|
Year of publication | 2021 |
Type | Conference abstract |
MU Faculty or unit | |
Citation | |
Related projects: |